<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:34:45Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9290603" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9290603</identifier>
        <datestamp>2022-07-20</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="mus27354" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Muscle Nerve</journal-id>
              <journal-id journal-id-type="iso-abbrev">Muscle Nerve</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1097-4598</journal-id>
              <journal-id journal-id-type="publisher-id">MUS</journal-id>
              <journal-title-group>
                <journal-title>Muscle &amp; Nerve</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0148-639X</issn>
              <issn pub-type="epub">1097-4598</issn>
              <publisher>
                <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
                <publisher-loc>Hoboken, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9290603</article-id>
              <article-id pub-id-type="pmcid">PMC9290603</article-id>
              <article-id pub-id-type="pmc-uid">9290603</article-id>
              <article-id pub-id-type="pmid">34129236</article-id>
              <article-id pub-id-type="pmid">34129236</article-id>
              <article-id pub-id-type="doi">10.1002/mus.27354</article-id>
              <article-id pub-id-type="publisher-id">MUS27354</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Clinical Research Short Report</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Research Short Reports</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Long‚Äêterm efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis</article-title>
                <alt-title alt-title-type="left-running-head">Sansone et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="mus27354-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Sansone</surname>
                    <given-names>Valeria A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="mus27354-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>valesans65@gmail.com</email>
                  </address>
                </contrib>
                <contrib id="mus27354-cr-0002" contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Nicholas E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3917-4257</contrib-id>
                  <xref rid="mus27354-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="mus27354-cr-0003" contrib-type="author">
                  <name>
                    <surname>Hanna</surname>
                    <given-names>Michael G.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="mus27354-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="mus27354-cr-0004" contrib-type="author">
                  <name>
                    <surname>Ciafaloni</surname>
                    <given-names>Emma</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="mus27354-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="mus27354-cr-0005" contrib-type="author">
                  <name>
                    <surname>Statland</surname>
                    <given-names>Jeffrey M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0790-5315</contrib-id>
                  <xref rid="mus27354-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="mus27354-cr-0006" contrib-type="author">
                  <name>
                    <surname>Shieh</surname>
                    <given-names>Perry B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7145-7663</contrib-id>
                  <xref rid="mus27354-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="mus27354-cr-0007" contrib-type="author">
                  <name>
                    <surname>Cohen</surname>
                    <given-names>Fredric</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="mus27354-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="mus27354-cr-0008" contrib-type="author">
                  <name>
                    <surname>Griggs</surname>
                    <given-names>Robert C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="mus27354-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="mus27354-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Neuromuscular Omnicentre, Neurorehabilitation Unit</named-content>
                <institution>University of Milan, Niguarda Hospital</institution>
                <city>Milan</city>
                <country country="IT">Italy</country>
              </aff>
              <aff id="mus27354-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>Virginia Commonwealth University</institution>
                <city>Richmond</city>
                <named-content content-type="country-part">Virginia</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="mus27354-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases</named-content>
                <institution>UCL Institute of Neurology</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="mus27354-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>University of Rochester Medical Center</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">New York</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="mus27354-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>University of Kansas Medical Center</institution>
                <city>Kansas City</city>
                <named-content content-type="country-part">Kansas</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="mus27354-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>Ronald Reagan UCLA Medical Center</institution>
                <city>Los Angeles</city>
                <named-content content-type="country-part">California</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="mus27354-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>Strongbridge Biopharma</institution>
                <city>Trevose</city>
                <named-content content-type="country-part">Pennsylvania</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Valeria A. Sansone, Neuromuscular Omnicentre, Neurorehabilitation Unit, University of Milan, Niguarda Hospital, Piazza Ospedale Maggiore, 3, Milano 20162, Italy.<break/>
Email: <email>valesans65@gmail.com</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>09</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>64</volume>
              <issue seq="150">3</issue>
              <issue-id pub-id-type="doi">10.1002/mus.v64.3</issue-id>
              <fpage>342</fpage>
              <lpage>346</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>04</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="received">
                  <day>23</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>13</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2021 Wiley Periodicals, LLC.-->
                <copyright-statement content-type="article-copyright">¬© 2021 The Authors. <italic toggle="yes">Muscle &amp; Nerve</italic> published by Wiley Periodicals LLC.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‚Äêcommercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:MUS-64-342.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="mus27354-sec-0001">
                  <title>Introduction/Aim</title>
                  <p>Long‚Äêterm efficacy and safety of dichlorphenamide (DCP) were characterized in patients with primary periodic paralysis (PPP).</p>
                </sec>
                <sec id="mus27354-sec-0002">
                  <title>Methods</title>
                  <p>Patients with PPP in a double‚Äêblind, placebo‚Äêcontrolled study were randomly assigned to receive DCP 50‚Äâmg twice daily or placebo for 9‚Äâweeks, followed by a 52‚Äêweek open‚Äêlabel DCP treatment phase (DCP/DCP and placebo/DCP populations). Efficacy (attack rate, severity‚Äêweighted attack rate) and safety were assessed in patients completing the study (61‚Äâweeks). In this post hoc analysis, efficacy and safety data were pooled from hyperkalemic and hypokalemic substudies.</p>
                </sec>
                <sec id="mus27354-sec-0003">
                  <title>Results</title>
                  <p>Sixty‚Äêthree adults (age, 19‚Äê76‚Äâyears) completed the double‚Äêblind phase; 47 (74.6%) of these patients completed 61‚Äâweeks. There were median decreases in weekly attack and severity‚Äêweighted attack rates from baseline to week 61 (DCP/DCP [n¬†=¬†25], ‚àí1.00 [<italic toggle="no">P</italic>‚Äâ&lt;‚Äâ.0001]; placebo/DCP [n¬†=¬†20], ‚àí0.63 [<italic toggle="no">P</italic>¬†=¬†.01] and DCP/DCP, ‚àí2.25 [<italic toggle="no">P</italic>‚Äâ&lt;‚Äâ.0001]; placebo/DCP, ‚àí1.69 [<italic toggle="no">P</italic>¬†=¬†.01]). Relatively smaller median decreases in weekly attack and severity‚Äêweighted attack rates occurred from weeks 9 to 61 among patients receiving DCP continuously (n¬†=¬†26; ‚àí0.14 [<italic toggle="no">P</italic>¬†=¬†.1] and ‚àí0.24 [<italic toggle="no">P</italic>¬†=¬†.09]) than among those switching from placebo to DCP after 9‚Äâweeks (n¬†=¬†16; ‚àí1.04 [<italic toggle="no">P</italic>¬†=¬†.049] and ‚àí2.72 [<italic toggle="no">P</italic>¬†=¬†.08]). Common adverse events (AEs) were paresthesia and cognition‚Äêrelated events, which typically first occurred within 1¬†month of blinded treatment initiation and in rare cases led to treatment discontinuation. Dose reductions were frequently associated with common AE resolution.</p>
                </sec>
                <sec id="mus27354-sec-0004">
                  <title>Discussion</title>
                  <p>One‚Äêyear open‚Äêlabel DCP treatment after a 9‚Äêweek randomized, controlled study confirmed long‚Äêterm DCP remains safe and effective for chronic use. Tolerability issues (paresthesia, cognition‚Äêrelated AEs) were manageable in most patients.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="mus27354-kwd-0001">efficacy</kwd>
                <kwd id="mus27354-kwd-0002">hypokalemic periodic</kwd>
                <kwd id="mus27354-kwd-0003">paralysis</kwd>
                <kwd id="mus27354-kwd-0004">paralysis</kwd>
                <kwd id="mus27354-kwd-0005">safety</kwd>
                <kwd id="mus27354-kwd-0006">weakness</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>FDA Orphan Drug Program</funding-source>
                  <award-id>FD‚ÄêR‚Äê000821</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>NIH National Institute of Neurological Disorders and Stroke</funding-source>
                  <award-id>grant R01 NS045686</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>Strongbridge Biopharma funded post hoc analysis, funded technical editorial assistance</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="0"/>
                <table-count count="3"/>
                <page-count count="23"/>
                <word-count count="3338"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>September 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:18.07.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="mus27354-cit-9001"><string-name><surname>Sansone</surname><given-names>VA</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>NE</given-names></string-name>, <string-name><surname>Hanna</surname><given-names>MG</given-names></string-name>, et al. <article-title>Long‚Äêterm efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis</article-title>. <source>Muscle &amp; Nerve</source>. <year>2021</year>;<volume>64</volume>:<fpage>342</fpage>‚Äì<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1002/mus.27354</pub-id>
<pub-id pub-id-type="pmid">34129236</pub-id></mixed-citation>
              </p>
              <fn-group id="mus27354-ntgp-0001">
                <fn id="mus27354-note-0001">
                  <p>This research was presented in part at the Muscle Study Group Annual Scientific Meeting, September 2018, Oxford, UK, and at the 71st Annual Meeting of the American Academy of Neurology, May 2019, Philadelphia, Pennsylvania.</p>
                </fn>
                <fn id="mus27354-note-1002">
                  <p><bold>Funding information</bold> FDA Orphan Drug Program, Grant/Award Number: FD‚ÄêR‚Äê000821; NIH National Institute of Neurological Disorders and Stroke, Grant/Award Number: grant R01 NS045686; Strongbridge Biopharma funded post hoc analysis, funded technical editorial assistance</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="mus27354-body-0001">
            <def-list list-content="abbreviations" id="mus27354-lp-0001">
              <title>Abbreviations</title>
              <def-item>
                <term id="mus27354-li-0001">AE</term>
                <def id="mus27354-li-0002">
                  <p>adverse event</p>
                </def>
              </def-item>
              <def-item>
                <term id="mus27354-li-0003">DCP</term>
                <def id="mus27354-li-0004">
                  <p>dichlorphenamide</p>
                </def>
              </def-item>
              <def-item>
                <term id="mus27354-li-0005">ITT</term>
                <def id="mus27354-li-0006">
                  <p>intent to treat</p>
                </def>
              </def-item>
              <def-item>
                <term id="mus27354-li-0007">NA</term>
                <def id="mus27354-li-0008">
                  <p>not applicable</p>
                </def>
              </def-item>
              <def-item>
                <term id="mus27354-li-0009">PPP</term>
                <def id="mus27354-li-0010">
                  <p>primary periodic paralysis</p>
                </def>
              </def-item>
            </def-list>
            <sec id="mus27354-sec-0005">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Primary periodic paralyses (PPP; hyperkalemic and hypokalemic paralysis) are rare, hereditary skeletal muscle ion channelopathies that lead to attacks of muscle weakness.<xref rid="mus27354-bib-0001" ref-type="bibr"><sup>1</sup></xref> Management of PPP includes long‚Äêterm pharmacologic therapy to minimize attack frequency and severity.<xref rid="mus27354-bib-0001" ref-type="bibr"><sup>1</sup></xref> The oral carbonic anhydrase inhibitor dichlorphenamide (DCP) is approved for treatment of hyperkalemic and hypokalemic periodic paralyses and related variants.<xref rid="mus27354-bib-0001" ref-type="bibr">1</xref>, <xref rid="mus27354-bib-0002" ref-type="bibr">2</xref>
</p>
              <p>Two randomized, double‚Äêblind, placebo‚Äêcontrolled studies, each with hyperkalemic and hypokalemic PPP substudies, demonstrated the effectiveness of DCP to prevent attacks of muscle weakness. The first study demonstrated that 9‚Äêweek daily DCP treatment decreased attack frequency and severity in 73 patients with hypokalemic and hyperkalemic paralysis (age, 10‚Äê75‚Äâyears).<xref rid="mus27354-bib-0003" ref-type="bibr"><sup>3</sup></xref> In the second study, HYPHOP, daily DCP treatment reduced the frequency, severity, and duration of paralytic attacks in 65 adults during weeks 2 to 9 of a 9‚Äêweek double‚Äêblind, placebo‚Äêcontrolled treatment period among patients with hypokalemic paralysis, and also during weeks 54 to 61 of a 1‚Äêyear open‚Äêlabel extension.<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref> Common adverse events (AEs) in both studies were paresthesia and cognitive changes (ie, confusion, depression, disorientation, memory issues, slowed mentation).<xref rid="mus27354-bib-0003" ref-type="bibr">3</xref>, <xref rid="mus27354-bib-0004" ref-type="bibr">4</xref> However, as the number of patients within each disease phenotype was relatively small by week 61, the current analysis addresses this sample size limitation by pooling key study data from the disease phenotype substudies to examine persistency of treatment benefit and further characterize the tolerability of DCP in PPP using pooled data from hyperkalemic and hypokalemic substudies of HYPHOP.<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref>
</p>
            </sec>
            <sec id="mus27354-sec-0006">
              <label>2</label>
              <title>METHODS</title>
              <sec id="mus27354-sec-0007">
                <label>2.1</label>
                <title>Study design and patients</title>
                <p>Population and study details from HYPHOP have been described elsewhere.<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref> Briefly, adults with hyperkalemic or hypokalemic PPP were randomized to receive double‚Äêblind DCP 50‚Äâmg or placebo twice daily for 9‚Äâweeks, followed by 52‚Äêweek open‚Äêlabel DCP treatment (DCP/DCP and placebo/DCP populations, respectively).<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref> In the double‚Äêblind phase, patients treated with DCP at enrollment continued their current DCP dose; those treated with acetazolamide received a DCP dose equivalent to 20% of acetazolamide dosing.<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref> After 9‚Äâweeks, investigators could reduce or increase DCP dosing as needed. The HYPHOP (<ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> Identifier NCT00494507) protocol was approved by the institutional review boards of 12 study centers. All patients provided written informed consent.</p>
              </sec>
              <sec id="mus27354-sec-0008">
                <label>2.2</label>
                <title>Assessments and statistical analyses</title>
                <p>Study completers comprised patients in the intent‚Äêto‚Äêtreat (ITT) population (patients receiving at least one dose of double‚Äêblind or open‚Äêlabel DCP treatment) completing the 52‚Äêweek extension period. Changes in weekly attack rates and severity‚Äêweighted attack rates (ie, sum of attack severity scores from 1 to 10 divided by the number of weeks) from baseline to week 61 and from weeks 9 to 61 were analyzed.<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref> Within‚Äêtreatment changes were assessed using the Wilcoxon signed‚Äêrank test. Treatment comparisons were analyzed with the blocked Wilcoxon rank‚Äêsum test, adjusting for PPP type.</p>
                <p>AEs occurring during the 9‚Äêweek, double‚Äêblind phase and the 52‚Äêweek, open‚Äêlabel extension phase were summarized for the ITT population using the Medical Dictionary for Regulatory Activities version 11.0. For patients who received placebo during the double‚Äêblind phase, only AEs occurring during open‚Äêlabel DCP treatment were reported. Kaplan‚ÄêMeier methods were used to estimate the percentages of patients without an AE over time.</p>
              </sec>
            </sec>
            <sec id="mus27354-sec-0009">
              <label>3</label>
              <title>RESULTS</title>
              <p>The ITT population comprised 63 patients who received at least one dose of DCP. Of these, 47 completed 61‚Äâweeks of treatment. The majority of study completers were male and had hypokalemic PPP (Table¬†<xref rid="mus27354-tbl-0001" ref-type="table">1</xref>). The baseline median weekly attack rates and median severity‚Äêweighted attack rates were greater in the placebo/DCP group than in the DCP/DCP group. Median decreases in weekly attack and severity‚Äêweighted attack rates occurred from baseline to week 61 in both groups (Table¬†<xref rid="mus27354-tbl-0002" ref-type="table">2</xref>). Relatively smaller median decreases in weekly attack and severity‚Äêweighted attack rates occurred from weeks 9 to 61 among participants receiving DCP continuously than among those switching from placebo to DCP after 9‚Äâweeks. Median attack and severity‚Äêweighted attack rates did not differ significantly between treatments at week 61 (Table¬†<xref rid="mus27354-tbl-0002" ref-type="table">2</xref> and Figure¬†<xref rid="mus27354-supitem-0002" ref-type="supplementary-material">S1</xref>).</p>
              <table-wrap position="float" id="mus27354-tbl-0001" content-type="TABLE">
                <label>TABLE 1</label>
                <caption>
                  <p>Patient disposition and double‚Äêblind baseline demographic and disease state characteristics</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="left" char=" (‚Äì" span="1"/>
                  <col align="left" char="left" span="1"/>
                  <col align="left" char=" (‚Äì" span="1"/>
                  <col align="left" char=" (‚Äì" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Parameter</th>
                      <th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">ITT population (n¬†=¬†63)</th>
                      <th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Study completer population (n¬†=¬†47)</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1">DCP/DCP (n¬†=¬†36)</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Placebo/DCP (n¬†=¬†27)</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">DCP/DCP (n¬†=¬†26)</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Placebo/DCP (n¬†=¬†21)</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patient disposition, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Completion of 9‚Äêweek double‚Äêblind phase</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">31 (86.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">27 (100)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Completion of 52‚Äêweek open‚Äêlabel phase</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">26 (72.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">21 (77.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age, years</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean (SD)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">42.9 (13.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">45.2 (15.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">40.9 (14.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">43.4 (15.9)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">19‚Äê76</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">19‚Äê76</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">19‚Äê76</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">19‚Äê76</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Male, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">22 (61.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">17 (63.0)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">17 (65.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">13 (61.9)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Race, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">30 (83.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">23 (85.2)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">22 (84.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">17 (81.0)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">4 (11.1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2 (7.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">3 (11.5)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2 (9.5)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2 (5.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1 (3.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1 (3.8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not reported</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1 (3.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1 (4.8)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Type of PPP, n (%)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hypokalemic</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">24 (66.7)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">19 (70.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">17 (65.4)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">14 (66.7)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hyperkalemic</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">12 (33.3)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">8 (29.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">9 (34.6)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">7 (33.3)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Median weekly attack rate</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1.75</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2.25<xref rid="mus27354-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">1.75</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">3.00<xref rid="mus27354-note-0004" ref-type="table-fn"><sup>b</sup></xref>
</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Median severity‚Äêweighted weekly attack rate</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">3.25</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.88<xref rid="mus27354-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">2.25</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">5.88<xref rid="mus27354-note-0005" ref-type="table-fn"><sup>c</sup></xref>
</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="mus27354-ntgp-0002">
                  <fn id="mus27354-note-0002">
                    <p>Abbreviations: DCP, dichlorphenamide; ITT, intent‚Äêto‚Äêtreat; NA, not applicable; PPP, primary periodic paralysis; SD, standard deviation.</p>
                  </fn>
                  <fn id="mus27354-note-0003">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p><italic toggle="yes">P</italic>¬†=¬†.5 (between‚Äêtreatment comparison for the ITT population based on blocked Wilcoxon rank‚Äêsum test).</p>
                  </fn>
                  <fn id="mus27354-note-0004">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p><italic toggle="yes">P</italic>¬†=¬†.2 (between‚Äêtreatment comparison for the study completer population based on blocked Wilcoxon rank‚Äêsum test).</p>
                  </fn>
                  <fn id="mus27354-note-0005">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p><italic toggle="yes">P</italic>¬†=¬†.3 (between‚Äêtreatment comparison for the study completer population based on blocked Wilcoxon rank‚Äêsum test).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="mus27354-tbl-0002" content-type="TABLE">
                <label>TABLE 2</label>
                <caption>
                  <p>Summary of efficacy (study completer population)</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="char" char="." span="1"/>
                  <col align="char" char="." span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">DCP/DCP (n¬†=¬†26)</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Placebo/DCP (n¬†=¬†21)</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Median weekly attack rate</td>
                      <td align="char" valign="top" rowspan="1" colspan="1"/>
                      <td align="char" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1.75<xref rid="mus27354-note-0007" ref-type="table-fn"><sup>a</sup></xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3.00<xref rid="mus27354-note-0008" ref-type="table-fn"><sup>b</sup></xref>
</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 9</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.32</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2.13<xref rid="mus27354-note-0009" ref-type="table-fn"><sup>c</sup></xref>
</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 61<xref rid="mus27354-note-0010" ref-type="table-fn"><sup>d</sup></xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.06</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.25</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median change from baseline to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí1.00</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí0.63</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median percent decrease from baseline to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">93.8</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">75.0</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value of the median decrease</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">&lt;.0001</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">.01</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median change from week 9 to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí0.14</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí1.04</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median percent decrease from week 9 to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">77.1</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">62.6</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value of the median decrease</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">.1</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">.049</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Median severity‚Äêweighted attack rate</td>
                      <td align="char" valign="top" rowspan="1" colspan="1"/>
                      <td align="char" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2.25<xref rid="mus27354-note-0007" ref-type="table-fn"><sup>a</sup></xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5.88<xref rid="mus27354-note-0008" ref-type="table-fn"><sup>b</sup></xref>
</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 9</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.58</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5.02<xref rid="mus27354-note-0009" ref-type="table-fn"><sup>c</sup></xref>
</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 61<xref rid="mus27354-note-0011" ref-type="table-fn"><sup>e</sup></xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.06</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0.50</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median change from baseline to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí2.25</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí1.69</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median percent decrease from baseline to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">97.1</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">80.8</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value of the median decrease</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">&lt;.0001</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">.01</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median change from week 9 to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí0.24</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">‚àí2.72</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median percent decrease from week 9 to week 61</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">72.6</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">57.8</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value of the median decrease</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">.09</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">.08</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="mus27354-ntgp-0003">
                  <fn id="mus27354-note-0006">
                    <p>Abbreviations: DCP, dichlorphenamide.</p>
                  </fn>
                  <fn id="mus27354-note-0007">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>n¬†=¬†25 (diary data missing for 1 patient).</p>
                  </fn>
                  <fn id="mus27354-note-0008">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>n¬†=¬†20 (diary data missing for 1 patient).</p>
                  </fn>
                  <fn id="mus27354-note-0009">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>n¬†=¬†16 (5 patients reached the endpoint of acute worsening of attacks during the double‚Äêblind phase, necessitating protocol‚Äêspecified withdrawal and initiation of participation in the open‚Äêlabel extension phase).<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref>
</p>
                  </fn>
                  <fn id="mus27354-note-0010">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p><italic toggle="yes">P</italic>¬†=¬†.04 for the between‚Äêtreatment difference for the change from week 9 to week 61. <italic toggle="yes">P</italic>¬†=¬†.14 for between‚Äêtreatment difference at week 61 (blocked Wilcoxon rank‚Äêsum test).</p>
                  </fn>
                  <fn id="mus27354-note-0011">
                    <label>
                      <sup>e</sup>
                    </label>
                    <p><italic toggle="yes">P</italic>¬†=¬†.08 for the between‚Äêtreatment difference at week 61 (blocked Wilcoxon rank‚Äêsum test).</p>
                  </fn>
                  <fn id="mus27354-note-0211">
                    <p>[Correction added on August 18, 2021 after first online publication: The values in the first part of Table 2 have been moved down by one row.]</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Approximately three quarters of patients reported at least one AE during DCP treatment (Table¬†<xref rid="mus27354-tbl-0003" ref-type="table">3</xref>), most commonly paresthesia. AEs reported with placebo have been described previously.<xref rid="mus27354-bib-0004" ref-type="bibr"><sup>4</sup></xref> Fewer than half of the DCP‚Äêtreated patients reported at least one paresthesia over 61‚Äâweeks, the majority of whom had at least one event considered possibly related to the study drug, but none considered severe (Table¬†<xref rid="mus27354-supitem-0001" ref-type="supplementary-material">S1</xref>). [Correction added on August 18, 2021 after first online publication: The preceding sentence has been revised from, ‚Äú‚Ä¶, the majority of whom considered their AE(s) possibly related to the study drug‚Ä¶‚Äù.] Paresthesia prompted study discontinuation in a single patient, and approximately three quarters of patients reported resolution of the last reported paresthesia during the study. Six of 25 (24.0%) patients reporting paresthesia were managed with DCP dose reduction (range, 25‚Äê100 mg); of these, 5 (83.3%) had resolution after dose reduction. Onset of paresthesia typically was within the first month of receiving DCP (Figure¬†<xref rid="mus27354-supitem-0003" ref-type="supplementary-material">S2</xref>A and B).</p>
              <table-wrap position="float" id="mus27354-tbl-0003" content-type="TABLE">
                <label>TABLE 3</label>
                <caption>
                  <p>Summary of AEs with DCP treatment (ITT population)</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="char" char=" (" span="1"/>
                  <col align="char" char=" (" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Patients, n (%)</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1">AEs</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Baseline to week 61 (n¬†=¬†63)</th>
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Week 9 to week 61 (n¬†=¬†58)</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">‚â•1 AE</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">47 (74.6)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">35 (60.3)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">‚â•1 treatment‚Äêrelated AE</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">38 (60.3)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">20 (34.5)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">‚â•1 serious AE</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (6.3)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (5.2)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">AEs reported in ‚â•5% of patients in either treatment period</td>
                      <td align="char" valign="top" rowspan="1" colspan="1"/>
                      <td align="char" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Paresthesia</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">25 (39.7)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">9 (15.5)<xref rid="mus27354-note-0013" ref-type="table-fn"><sup>a</sup></xref>
</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cognitive disorder<xref rid="mus27354-note-0014" ref-type="table-fn"><sup>b</sup></xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">9 (14.3)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (8.6)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fall</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">7 (11.1)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">6 (10.3)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Headache</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">7 (11.1)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (5.2)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">6 (9.5)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (6.9)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Dysgeusia</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">6 (9.5)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (3.4)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">6 (9.5)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (3.4)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pruritus</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (7.9)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (3.4)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Rash</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">5 (7.9)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">2 (3.4)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Confusional state<xref rid="mus27354-note-0015" ref-type="table-fn"><sup>c</sup></xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (6.3)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Muscle spasms</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">4 (6.3)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">1 (1.7)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nasopharyngitis</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (4.8)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (5.2)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nephrolithiasis<xref rid="mus27354-note-0016" ref-type="table-fn"><sup>d</sup></xref>
</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (4.8)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (5.2)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pain in extremity</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (4.8)</td>
                      <td align="char" valign="top" rowspan="1" colspan="1">3 (5.2)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="mus27354-ntgp-0004">
                  <fn id="mus27354-note-0012">
                    <p>Abbreviations: AE, adverse event; DCP, dichlorphenamide; ITT, intent‚Äêto‚Äêtreat.</p>
                  </fn>
                  <fn id="mus27354-note-0013">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Eight patients received placebo during the 9‚Äêweek double‚Äêblind phase.</p>
                  </fn>
                  <fn id="mus27354-note-0014">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>AEs classified under Medical Dictionary for Regulatory Activities (MedDRA; version 11.0) Preferred Term ‚Äúcognitive disorder‚Äù include cognitive disturbance, cognitive impairment, confusion/feels foggier, fogginess, mental fog, and spacey/foggy.</p>
                  </fn>
                  <fn id="mus27354-note-0015">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>AEs classified under MedDRA (version 11.0) Preferred Term ‚Äúconfusional state‚Äù include confusion and mental confusion.</p>
                  </fn>
                  <fn id="mus27354-note-0016">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p>One patient discontinued from the study due to this AE, which was not associated with any visible ultrasound changes from baseline at the time of study withdrawal.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The second most common were cognition‚Äêrelated AEs, reported for approximately one quarter of DCP‚Äêtreated patients over 61‚Äâweeks (Table¬†<xref rid="mus27354-supitem-0001" ref-type="supplementary-material">S1</xref>). The majority of cognition‚Äêrelated AEs were mild, with severe events and AE‚Äêrelated study discontinuations rarely occurring. Approximately two thirds of patients with cognition‚Äêrelated AEs reported the last event resolved while they participated in the study. Six (37.5%) patients were managed with DCP dose reduction (range, 25‚Äê50‚Äâmg), with all having resolution thereafter. One patient discontinued treatment twice (ie, motor vehicle accident, hospitalization for thyroid cancer surgery), which resulted in a dose reduction from 150 to 0¬†mg each time; treatment was reinitiated, but an increase in DCP dosing from 150 to 200‚Äâmg resulted in cognitive disturbance, leading to a dose reduction to 150‚Äâmg. In addition to this patient, one patient increased DCP dosing after dose reduction (50‚Äâmg). Onset of cognition‚Äêrelated AEs typically was within the first month of DCP treatment (Figure¬†<xref rid="mus27354-supitem-0003" ref-type="supplementary-material"><bold>S2</bold></xref>C and D).</p>
              <p>Nephrolithiasis as an AE was reported by three patients in the study (Table¬†<xref rid="mus27354-tbl-0003" ref-type="table">3</xref>). One patient withdrew from the study due to this AE, although ultrasound did not indicate any changes from baseline in the appearance of the kidney stones at the time of study withdrawal. At baseline, eight patients had ultrasound evidence of nephrolithiasis. During treatment, one of the eight patients had an increase in size or number of kidney stones, whereas four had a decrease in the number of kidney stones during the study. Of the 57 patients with postbaseline data available for nephrolithiasis, 10 (17.5%) had an increase in the size or number of kidney stones. Only one of these 10 patients had baseline evidence of kidney stones. Incident nephrolithiasis was benign in all patients and was not associated with AEs.</p>
            </sec>
            <sec id="mus27354-sec-0010">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>These post‚Äêhoc analyses extend findings from the original HYPHOP study by demonstrating that efficacy was maintained over the 61‚Äêweek study with no evidence of waning over time. Indeed, there was evidence of further reduction in median weekly attacks among continuous DCP users to nearly none by study end. Likewise, patients who were switched from placebo to open‚Äêlabel DCP after week 9 nearly ‚Äúcaught up‚Äù with those who had been continuously treated with DCP over the entire study.</p>
              <p>AE analyses indicated no new safety signals during the final 52‚Äâweeks of the study vs the first 9‚Äâweeks, and paresthesia and cognition‚Äêrelated AEs, which were the most commonly reported AEs during the first 9‚Äâweeks, were generally not reported during the extension. Clinicians can advise patients starting DCP that most patients who had one of these events initially reported it within the first month of treatment. Temporary dose reduction seems to be a reasonable maneuver to manage bothersome paresthesia or cognition‚Äêrelated AEs, given that patients with these AEs who were investigator‚Äêmanaged with dose reduction had subsequent symptom resolution. Likewise, it may be helpful to titrate slowly when escalation above the starting dose is needed to achieve efficacy. Treatment was associated with development of incident nephrolithiasis, which was mostly benign in nature, and an increase in stone size or growth during treatment was common. Surprisingly, among the eight patients with prevalent nephrolithiasis at study entry, kidney stone size or number was more often reduced rather than increased during treatment, suggesting that the stones in these patients may not have been influenced by the same pathogenesis that led to incident stone formation and growth.</p>
              <p>Limitations include subjective measures of efficacy, lack of a comparator arm throughout the study, and lack of interim efficacy determination between weeks 9 and 61.</p>
              <p>In conclusion, these analyses support long‚Äêterm daily DCP to prevent attacks of muscle weakness in PPP, and they provide potentially useful information for patient counseling and management.</p>
            </sec>
            <sec sec-type="COI-statement" id="mus27354-sec-0012">
              <title>CONFLICT OF INTEREST</title>
              <p>Funding for medical writing and editorial assistance was provided by Strongbridge Biopharma, Trevose, PA. V.A.S. has served as a scientific consultant on advisory boards for AveXis, Biogen Idec, Dyne Therapeutics, PTC Therapeutics, Santhera, Sarepta Therapeutics, and for the Italian Spinal Muscular Atrophy Association. N.E.J. has received research support from the Centers for Disease Control and Prevention, Dyne Therapeutics, US Food and Drug Administration, Fulcrum Therapeutics, Muscular Dystrophy Association, Myotonic Dystrophy Foundation, National Institute of Neurological Disorders and Stroke, and Sarepta Therapeutics, and has served as a consultant for AMO Pharma, AskBio, Dyne Therapeutics, Sarepta Therapeutics, Triplet Therapeutics, and Strongbridge Biopharma. E.C. has received personal compensation for serving on advisory boards and/or as a consultant for AveXis, Biogen, Pfizer, PTC Therapeutics, Santhera, Sarepta Therapeutics, and Strongbridge Biopharma, and has received research support from the Centers for Disease Control and Prevention, Cure SMA, US Food and Drug Administration, the Muscular Dystrophy Association, National Institutes of Health, PCORI, Parent Project Muscular Dystrophy, PTC Therapeutics, Santhera, and Sarepta Therapeutics. J.M.S. has received research support from the FSHD Society, Muscular Dystrophy Association, and the National Institutes of Health, and has served as a consultant for Acceleron Pharma, Expansion Therapeutics, Fulcrum Therapeutics, Genea Biocells, and Strongbridge Biopharma. P.B.S. has received grant funding from Acceleron Pharma, Biogen, Fulcrum Therapeutics, the Muscular Dystrophy Association, the National Institutes of Health (NIH), Pfizer, PTC Therapeutics, Roche, Sanofi, and Sarepta Therapeutics, and has served as a consultant for Argenx, Alexion Pharmaceuticals, AveXis, Biogen, Catalyst Pharmaceuticals, Genentech, and Sarepta Therapeutics. F.C. is an employee of Strongbridge Biopharma. R.C.G. has received grant funding from the Muscular Dystrophy Association, the NIH, Parent Project Muscular Dystrophy, PTC Therapeutics, and Sarepta Therapeutics; served as a consultant for PTC Therapeutics, Sarepta Therapeutics, and Strongbridge Biopharma, and served on a data safety monitoring board for Solid Biosciences and Santhera Pharmaceuticals. M.G.H. declares no conflicts of interest.</p>
            </sec>
            <sec id="mus27354-sec-0013">
              <title>ETHICAL PUBLICATION STATEMENT</title>
              <p>We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="mus27354-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>TABLE S1</bold> Characterization of paresthesia and cognition‚Äêrelated adverse events during DCP treatment</p>
                </caption>
                <media xlink:href="MUS-64-342-s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="mus27354-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p><bold>FIGURE S1</bold> Summary of efficacy, study completer population: median weekly attack rates (A) and severity‚Äêweighted weekly attack rates (B). Rates at week 9 and week 61 are the mean of the weekly attack rates (A) or severity‚Äêweighted attack rates (B) at weeks 2 to 9 and weeks 54 to 61. For patients with less than 8‚Äâweeks of completed diary entries, missing data were considered as days without an attack in a particular week. Abbreviations: DCP,¬†dichlorphenamide; PBO,¬†placebo. <sup>a</sup>n¬†=¬†20; <sup>b</sup>n¬†=¬†25; <sup>c</sup>n¬†=¬†16; <sup>d</sup>n¬†=¬†26; <sup>e</sup>n¬†=¬†21; <sup>f</sup>
<italic toggle="yes">p</italic>¬†=¬†.01; <sup>g</sup>
<italic toggle="yes">P</italic> value based on median decrease from baseline to week 61 within a group; <sup>h</sup>
<italic toggle="yes">P</italic>‚Äâ&lt;‚Äâ.0001. Bars represent standard error.</p>
                </caption>
                <media xlink:href="MUS-64-342-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="mus27354-supitem-0003" position="float" content-type="local-data">
                <caption>
                  <p><bold>FIGURE S2</bold> Time to onset of paresthesia during double‚Äêblind (A) and open‚Äêlabel extension (B) phases and time to onset of cognition‚Äêrelated AEs during double‚Äêblind (C) and open‚Äêlabel extension (D) phases. Abbreviations: AE,¬†adverse event; DCP,¬†dichlorphenamide; PBO,¬†placebo.</p>
                </caption>
                <media xlink:href="MUS-64-342-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="mus27354-sec-0011">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors thank all the investigators, coinvestigators, and research nurses/study coordinators who conducted the study and all the patients who participated in the study. Medical writing and editorial assistance were provided by Mary Beth Moncrief, PhD, and Sophie Bolick, PhD, Synchrony Medical Communications, LLC, West Chester, PA, under direction of the authors. Funding for this assistance was provided by Strongbridge Biopharma, Trevose, PA. The authors had full editorial independence.</p>
            </ack>
            <sec sec-type="data-availability" id="mus27354-sec-0015">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>Research data are not shared.</p>
            </sec>
            <ref-list id="mus27354-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="mus27354-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="mus27354-cit-0001"><string-name><surname>Statland</surname><given-names>JM</given-names></string-name>, <string-name><surname>Fontaine</surname><given-names>B</given-names></string-name>, <string-name><surname>Hanna</surname><given-names>MG</given-names></string-name>, et al. <article-title>Review of the diagnosis and treatment of periodic paralysis</article-title>. <source>Muscle Nerve.</source><year>2018</year>;<volume>57</volume>:<fpage>522</fpage>‚Äê<lpage>530</lpage>.<pub-id pub-id-type="pmid">29125635</pub-id></mixed-citation>
              </ref>
              <ref id="mus27354-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="miscellaneous" id="mus27354-cit-0002"><collab collab-type="authors">Keveyis¬Æ</collab><article-title>(dichlorphenamide) tablets for oral use [package insert]. Trevose, PA: Strongbridge US</article-title>; <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="mus27354-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="mus27354-cit-0003"><string-name><surname>Tawil</surname><given-names>R</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>MP</given-names></string-name>, <string-name><surname>Brown</surname><given-names>R</given-names><suffix>Jr</suffix></string-name>, et al. <article-title>Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis</article-title>. <source>Ann Neurol.</source><year>2000</year>;<volume>47</volume>:<fpage>46</fpage>‚Äê<lpage>53</lpage>.<pub-id pub-id-type="pmid">10632100</pub-id></mixed-citation>
              </ref>
              <ref id="mus27354-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="mus27354-cit-0004"><string-name><surname>Sansone</surname><given-names>VA</given-names></string-name>, <string-name><surname>Burge</surname><given-names>J</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>MP</given-names></string-name>, et al. <article-title>Randomized, placebo‚Äêcontrolled trials of dichlorphenamide in periodic paralysis</article-title>. <source>Neurology.</source><year>2016</year>;<volume>86</volume>:<fpage>1408</fpage>‚Äê<lpage>1416</lpage>.<pub-id pub-id-type="pmid">26865514</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
